See more : ContraFect Corporation (CFRX) Income Statement Analysis – Financial Results
Complete financial analysis of Galera Therapeutics, Inc. (GRTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Galera Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Enjin Co., Ltd. (7370.T) Income Statement Analysis – Financial Results
- Renovare Environmental, Inc. (BHTG) Income Statement Analysis – Financial Results
- Beardsell Limited (BEARDSELL.NS) Income Statement Analysis – Financial Results
- Educational Development Corporation (EDUC) Income Statement Analysis – Financial Results
- Prominence Energy Ltd (PRM.AX) Income Statement Analysis – Financial Results
Galera Therapeutics, Inc. (GRTX)
About Galera Therapeutics, Inc.
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 259.00K | 114.00K | 778.00K | 368.00K | 267.00K | 127.00K | 84.00K |
| Gross Profit | -259.00K | -114.00K | -778.00K | -368.00K | -267.00K | -127.00K | -84.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 24.12M | 31.01M | 52.42M | 54.85M | 42.33M | 18.66M | 20.59M |
| General & Administrative | 22.84M | 20.21M | 20.95M | 15.71M | 8.36M | 5.59M | 3.50M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.84M | 20.21M | 20.95M | 15.71M | 8.36M | 5.59M | 3.50M |
| Other Expenses | 0.00 | -11.07M | -7.17M | -3.68M | -1.25M | 0.00 | 0.00 |
| Operating Expenses | 46.95M | 51.23M | 73.37M | 70.55M | 50.69M | 24.26M | 24.09M |
| Cost & Expenses | 46.95M | 51.23M | 73.37M | 70.55M | 50.69M | 24.26M | 24.09M |
| Interest Income | 9.82M | 506.00K | 32.00K | 1.17M | 1.82M | 606.00K | 193.00K |
| Interest Expense | 0.00 | 11.57M | 7.19M | 4.88M | 3.03M | 220.00K | 0.00 |
| Depreciation & Amortization | 259.00K | 114.00K | 778.00K | 368.00K | 267.00K | 127.00K | 84.00K |
| EBITDA | -46.69M | -50.61M | -72.56M | -69.01M | -50.69M | -23.52M | -23.82M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -46.95M | -51.23M | -73.37M | -70.55M | -50.69M | -24.26M | -24.09M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -12.13M | -11.07M | -7.17M | -3.68M | -1.25M | 356.00K | 189.00K |
| Income Before Tax | -59.08M | -62.29M | -80.53M | -74.23M | -51.94M | -23.90M | -23.91M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -70.00K | 7.19M | -16.00K | -9.00K | -223.00K | -360.00K |
| Net Income | -59.08M | -62.22M | -87.73M | -74.22M | -51.93M | -23.68M | -23.55M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.33 | -2.30 | -3.40 | -2.98 | -2.09 | -1.22 | -1.55 |
| EPS Diluted | -1.33 | -2.30 | -3.40 | -2.98 | -2.09 | -1.22 | -1.55 |
| Weighted Avg Shares Out | 44.55M | 27.09M | 25.79M | 24.87M | 24.81M | 19.36M | 15.22M |
| Weighted Avg Shares Out (Dil) | 44.55M | 27.09M | 25.79M | 24.87M | 24.81M | 19.36M | 15.22M |
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
Galera Therapeutics shares plummet after FDA rejects drug for cancer treatment side effect
Why Is Galera Therapeutics (GRTX) Stock Down 83% Today?
Galera shares tank after US FDA declines to approve inflammation disease drug
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese
Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Galera Therapeutics: A Possible Solution To Severe Oral Mucositis In Head And Neck Cancer Patients
Piper Sandler Initiates Coverage of Galera Therapeutics With Overweight Recommendation
Galera to Present at Piper Sandler Annual Healthcare Conference
Galera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
Source: https://incomestatements.info
Category: Stock Reports